COX-2: Where are we in 2003? - Distinction from NSAIDs becoming blurred
AUTOR(ES)
Day, Richard
FONTE
BioMed Central
RESUMO
The distinction between cyclooxygenase-2-selective inhibitors (CSIs) and nonsteroidal anti-inflammatory drugs ultimately must be clinical and must be clinically and economically relevant. This distinction needs to be demonstrated in a substantial and clinically relevant difference in the respective rates of serious adverse reactions of the upper gastrointestinal tract. Event-driven, randomized, blinded, controlled trials with sufficient power are required to resolve uncertainties concerning the relative risk of thrombotic cardiovascular events in patients taking CSIs who have risk factors for these events. Patients and situations more representative of those in primary-care practice – elderly, comorbidities, comedication – need to be included in larger studies to provide a better understanding of the risks and benefits of CSIs.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=165043Documentos Relacionados
- Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
- Cox-2: Where are we in 2003? - The role of cyclooxygenase-2 in bone repair
- COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory disease
- COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients
- Iron health: where are we and where are we going?
